ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The investigators propose a proof-of-concept, pathogenesis-oriented, randomized,
placebo-controlled pilot study to assess whether the addition of an angiotensin converting
enzyme (ACE) inhibitor to standard Highly Active Antiretroviral Therapy (HAART) reverses
lymphoid fibrosis, and whether this leads to more effective HIV-specific host immune
responses and an accelerated clearance of the latent reservoir.